Alligator Bioscience Announces FDA Orphan Drug Designation For HLX22/AC101
Reuters
03-20
March 20 (Reuters) - Alligator Bioscience AB :: *ALLIGATOR BIOSCIENCE ANNOUNCES FDA ORPHAN DRUG DESIGNATION FOR HLX22/AC101 IN GASTRIC CANCER *UNDER TERMS OF LICENSE AGREEMENT, ALLIGATOR IS ENTITLED TO 35% OF ABCLON'S REVENUE FROM SUBLICENSE AGREEMENT WITH HENLIUS